

Supplementary Table S4. Summary of Death and Adverse Events of Special Interest

Summary of Death		No CNS Metastases N=15		CNS Metastases N=10		All patients N=25	
	Reasons for death	n	%	n	%	n	%
All deaths	Total	5	33	7	70	12	48
Deaths on treatment	Total	1	7	0	0	1	4
	Cardiogenic pulmonary edema ^a	1	7	0	0	1	4
Deaths within 30 days of treatment discontinuation	Total	1	7	5	50	6	24
	Acute subdural hemorrhage ^b	0	0	1	10	1	4
	Study disease	1	7	4	40	5	20
Deaths after >30 days of treatment discontinuation	Total	3	20	2	20	5	20
	Cardiac arrest ^a	1	7	0	0	1	4
	Study disease	2	13	2	20	4	16

	No CNS Metastases N=15		CNS Metastases N=10		All Patients N=25	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3
	n (%)					
Patients with ≥1 AESIs	14 (93)	7 (47)	7 (70)	2 (20)	21 (84)	9 (36)
Arterial thromboembolic events	1 (7)	1 (7)	1 (10)	0 (0)	2 (8)	1 (4)
Bleeding / hemorrhage events	7 (47)	0 (0)	3 (30)	1 (10)	10 (40)	1 (4)
Congestive heart failure	1 (7)	1 (7)	1 (10)	1 (10)	2 (8)	2 (8)
GI hemorrhage events	0 (0)	0 (0)	1 (10)	0 (0)	1 (4)	0 (0)
Hypertension	10 (67)	4 (27)	5 (50)	0 (0)	15 (60)	4 (16)
Liver injury / liver failure	6 (40)	1 (7)	2 (20)	0 (0)	8 (32)	1 (4)
Proteinuria	3 (20)	0 (0)	2 (20)	0 (0)	5 (20)	0 (0)
Pulmonary hemorrhage events	1 (7)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)

Renal failure	1 (7)	1 (7)	2 (20)	1 (10)	3 (12)	2 (8)
Venous thromboembolic events	1 (7)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)

^aDeemed unrelated to study treatment.

^bDeath of a 75-year-old patient following hospitalization for congestive heart failure who subsequently experienced a fatal subdural hemorrhage, deemed possibly related to treatment.

AESI, adverse event of special interest; CNS, central nervous system; GI, gastrointestinal; N, number of patients in population; n, number of patients in specified category.